AL-DAWAA MEDICAL SERVICES COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.5 SAR | +0.64% |
|
-1.36% | -10.68% |
| Apr. 30 | Aldawaa Medical Services Posts Higher Q1 Net Profit, Revenue | MT |
| Apr. 30 | Al-Dawaa Medical Services Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 6,112 | 8,993 | 8,032 | - | - |
| Enterprise Value (EV) 1 | 6,112 | 11,093 | 9,479 | 8,969 | 8,890 |
| P/E ratio | 20 x | 27.3 x | 19.9 x | 16.5 x | 14.7 x |
| Yield | - | - | 2.89% | 3.53% | 4.44% |
| Capitalization / Revenue | 1.14 x | 1.57 x | 1.28 x | 1.22 x | 1.15 x |
| EV / Revenue | 1.14 x | 1.93 x | 1.51 x | 1.36 x | 1.27 x |
| EV / EBITDA | 8.45 x | 13.4 x | 10.5 x | 9.08 x | 8.51 x |
| EV / FCF | - | 21.8 x | 15.8 x | 18 x | 18.1 x |
| FCF Yield | - | 4.59% | 6.32% | 5.55% | 5.51% |
| Price to Book | - | 6.85 x | 5.42 x | 5 x | 4.68 x |
| Nbr of stocks (in thousands) | 85,000 | 85,000 | 85,000 | - | - |
| Reference price 2 | 71.90 | 105.8 | 94.50 | 94.50 | 94.50 |
| Announcement Date | 3/26/23 | 3/18/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 5,034 | 5,372 | 5,741 | 6,266 | 6,591 | 7,006 |
| EBITDA 1 | - | 600.1 | 723.6 | 830.4 | 903.6 | 988.2 | 1,045 |
| EBIT 1 | - | 266.2 | 369 | 466.7 | 524.2 | 579.5 | 633.9 |
| Operating Margin | - | 5.29% | 6.87% | 8.13% | 8.37% | 8.79% | 9.05% |
| Earnings before Tax (EBT) 1 | - | 246 | - | 342.4 | 420 | 525.5 | 590 |
| Net income 1 | 246.4 | 239.1 | 305.4 | 329.2 | 403.3 | 487.9 | 545.5 |
| Net margin | - | 4.75% | 5.69% | 5.73% | 6.44% | 7.4% | 7.79% |
| EPS 2 | 1,232 | 2.810 | 3.590 | 3.870 | 4.744 | 5.739 | 6.414 |
| Free Cash Flow 1 | - | 291.7 | - | 508.9 | 599 | 498 | 490 |
| FCF margin | - | 5.79% | - | 8.86% | 9.56% | 7.56% | 6.99% |
| FCF Conversion (EBITDA) | - | 48.6% | - | 61.28% | 66.29% | 50.4% | 46.88% |
| FCF Conversion (Net income) | - | 121.96% | - | 154.58% | 148.54% | 102.07% | 89.83% |
| Dividend per Share 2 | - | 4.130 | - | - | 2.727 | 3.339 | 4.198 |
| Announcement Date | 12/22/21 | 3/31/22 | 3/26/23 | 3/18/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|
| Net sales 1 | - | 1,439 | 1,458 | 1,516 |
| EBITDA | - | - | 215.6 | - |
| EBIT 1 | - | 102 | 127.7 | 130.5 |
| Operating Margin | - | 7.09% | 8.76% | 8.61% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income 1 | 89.33 | 71.28 | 92.35 | 95.33 |
| Net margin | - | 4.95% | 6.33% | 6.29% |
| EPS | 1.050 | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 8/3/23 | 11/2/23 | 3/18/24 | 4/29/24 |
1SAR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 2,100 | 1,446 | 936 | 858 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | 2.528 x | 1.601 x | 0.9474 x | 0.8208 x |
| Free Cash Flow 1 | - | 292 | - | 509 | 599 | 498 | 490 |
| ROE (net income / shareholders' equity) | - | 22.8% | - | 27.3% | 29.3% | 30.8% | 31.6% |
| ROA (Net income/ Total Assets) | - | 6.31% | - | 7.15% | 8.25% | 9.78% | 9.58% |
| Assets 1 | - | 3,788 | - | 4,602 | 4,889 | 4,989 | 5,693 |
| Book Value Per Share 2 | - | 11.60 | - | 15.40 | 17.40 | 18.90 | 20.20 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 378 | - | 217 | 223 | 235 | 225 |
| Capex / Sales | - | 7.52% | - | 3.78% | 3.55% | 3.56% | 3.21% |
| Announcement Date | 12/22/21 | 3/31/22 | 3/26/23 | 3/18/24 | - | - | - |
1SAR in Million2SAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
94.5
SAR
Average target price
117.1
SAR
Spread / Average Target
+23.87%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.68% | 2.14B | |
| -23.53% | 11.73B | |
| +12.44% | 6.3B | |
| -25.24% | 6.29B | |
| -9.39% | 6B | |
| -2.48% | 4.63B | |
| +60.00% | 4.57B | |
| -6.67% | 3.89B | |
| -10.84% | 3.5B | |
| -6.41% | 3.04B |
- Stock Market
- Equities
- 4163 Stock
- Financials Al-Dawaa Medical Services Company